SCHEMBL4716129

SCHEMBL4716129

N#Cc1ccc(Cn2ccc3c2ccc(=O)n3-c2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
FNTA P49354 4/20 0.41
FNTB P49356 4/20 0.41
KMT2A Q03164 1/20 0.41
DHFR P00374 1/20 0.41
SLC2A1 P11166 1/20 0.41
PGGT1B P53609 3/20 0.41
POLB P06746 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
NPM1 P06748 1/20 0.39
CA12 O43570 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
ADORA2A P29274 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715546 0.87 L3MBTL1 (0.49) CYP11B1CYP11B2ALDH1A1ADORA2ACYP19A1
SCHEMBL4713845 0.87 BRD4 (0.46) HTTKMT2AKDM4EALDH1A1
SCHEMBL4714110 0.84 LMNA (0.44) CYP11B1CYP11B2LMNAHTTKMT2A
SCHEMBL5124227 0.83 SMN1; SMN2 (0.43) CYP11B1CYP11B2LMNAHTTKDM4E
SCHEMBL4715873 0.83 TP53 (0.46) CYP11B1CYP11B2LMNAHTTKMT2A
SCHEMBL5113137 0.81 HTR6 (0.44) LMNAHTTKDM4EALDH1A1
SCHEMBL4715863 0.80 CYP3A4 (0.46) HTTKMT2APOLBKDM4EALDH1A1
SCHEMBL4716315 0.78 ALDH1A1 (0.47) LMNAHTTPOLBKDM4EALDH1A1
SCHEMBL4761608 0.78 MAPT (0.36) LMNAHTTPOLBALDH1A1
SCHEMBL4716165 0.77 PIK3CD (0.40) LMNAHTTKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US claimed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US claimed
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed
EP-1549648-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS Celltech R & D Limited (GB) 2005-07-06 EP disclosed
WO-2004031188-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS CELLTECH R & D LIMITED (GB) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 CYP11B1 302/4885CYP11B2 339/4885LMNA 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.